Top Healthcare & Biotech Hedge Funds manage $95 Billion, Glenview Capital reclaims crown as Viking Retreats

December 4th, 2014
| More
The most recent Top Healthcare, Pharma and Biotech Focused Hedge Fund list has been released, revealing that the top 50 funds now manage $95 billion in U.S. equity assets. Over the quarter, Larry Robbins’ Glenview Capital reclaimed the top spot on the list from Andreas Halvorsen’s Viking Global. Greenwich-based Viking Global fell off the list, after having trimmed its healthcare sector allocation to just 24%.

Glenview Capital’s sector favorites once again include Thermo Fisher Scientific (TMO), Tenet Healthcare Corp (THC) and HCA Holdings Inc (HCA). Notably, over the quarter, Glenview purchased 1.7M shares of Endo Health Solutions (ENDP) and 921k shares of Aetna Inc (AET), increasing its stakes to $386M and $356M, respectively.

Renowned activist investor, Pershing Square Capital Management, grabbed the number two spot on the Top Healthcare, Pharma and Biotech List, having moved up a spot from last quarter. Bill Ackman’s sector picks are limited to large positions in just two stocks: Allergan Inc (AGN) and Zoetis Inc (ZTS). While Ackman has had an ongoing activist feud with Allergan, things are just getting started with animal health focused Zoetis, as he purchased his entire stake in the company over the past quarter.

Other top investors that lead the Top Healthcare, Pharma and Biotech Hedge Fund List include #3 OrbiMed Advisors and #4 Visium Asset Management LLC. The largest investments for OrbiMed Advisors, which is run by Samuel Isaly, include

Gilead Sciences Inc (GILD), Biogen Idec Inc (BIIB), Bristol-Myers Squibb (BMY), and Amgen (AMGN). Over the quarter, OribMed’s biggest sector buys were 313k shares of Shire Plc (SHPG) and 673k shares of Celgene Corp (CELG)

Ranking Methodology: The Top Healthcare, Pharmaceutical and Biotechnology Hedge Fund rankings are compiled on a quarterly basis using hedge fund firms’ overall U.S. equity assets under management. The list includes the top hedge funds that have more than 35% of their U.S. equity assets invested in U.S. listed Healthcare, Pharma & Biotech companies. To view the Top Healthcare, Pharma & Biotech Hedge Fund list in its entirety, please visit HedgeTracker’s Hedge Fund Portal.
For Detailed Investor Profiles on these Investors, click below:
Glenview Capital Management
OrbiMed Advisors
Pershing Square Capital Management
Visium Asset Management LLC
Related People: Jacob Gottlieb; Larry Robbins; Nicholas Botta; Roy J. Katzovicz; Samuel Isaly; Scott Ferguson*; William 'Bill' Ackman
Related Entities: Catalyst Investment Management ; Visium Credit Opportunities Fund; Visium Global Fund; Visium Long Bias Fund LP; Caduceus Asia Partners LP; Caduceus Capital LP; Eaton Vance Worldwide Health Sciences; Finsbury Worldwide Pharmaceutical; GCM Little Arbor Institutional Partners; GCM Little Arbor Master; GCM Little Arbor Partners; Glenview Capital Master; Glenview Capital Partners; Glenview Institutional Partners; Leucadia Corporation (NYSE: LUK); OrbiMed Associates; OrbiMed Capital; Pershing Square Capital; Pershing Square IV; Pershing Square LP; Visium Balanced Fund
Related Article Tags: Shareholder Activists, Corporate Raiders and Proxy Battles; Hedge Fund Spotlight Reports; Featured Article

More Recent Headlines

California’s Hedge Fund Gold Rush Stalls, Top Hedge Fund Assets fall just below $88 Billion

DE Shaw remains king; Renaissance and Icahn record double digit declines

GLG Partners names Neil Mason as Manager of its European Hedge Fund

Soo Kim and David Glazek’ Standard General Out to Fix Radio Shack & American Apparel

Ziad Tabet, Jabre Capital veteran, to Launch Event-Driven focused Amakor Capital Management

Graduates of Top MBA Programs Sold $2.5 billion of Stock during Q3

David Einhorn’s Greenlight Capital Reopens Gates to Existing and New Investor Capital

Leland Lim & Allan Bedwick’s recently launched Guard Capital Gains 11% in September

Israel Englander’s Millennium Management goes on a Commodities Hiring Spree

Top Small-Cap Focused Hedge Funds are up 14.4 percent year-to-date; Largest Funds both like Auxilium Pharmaceuticals